 | • レポートコード：MRC2Q12-19276 • 出版社/出版日：QYResearch / 2022年12月 • レポート形態：英文、PDF、97ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医薬品＆医療 |
| Single User | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,450,400 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 新型コロナウイルス感染症とロシア・ウクライナ戦争の影響により、注射用ニモジピンのグローバル市場は 2022にxxxドルと推定され、2028年までにxxxドルの規模に達し、2022年から2028年の予測期間中にxxx%のCAGRで成長すると予測されています。 注射用ニモジピンのアメリカ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 注射用ニモジピンの中国市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 注射用ニモジピンのヨーロッパ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 生産面において、本レポートは2017年から2022年までの注射用ニモジピンの生産、成長率、メーカー別市場シェア、地域別市場シェア、および2028年までの予測を調査しています。販売面において、本レポートは2017年から2022年までの地域別、企業別、タイプ別、アプリケーション別の注射用ニモジピンの売上および2028年までの予測に焦点を当てています。 注射用ニモジピンのグローバル主要企業には、Shanxi PUDE Pharmaceutical、Reyoung Pharmaceutical、Double-Crane Pharmaceutical(Hainan)、Shanxi Hengda Pharmaceutical、Kunming Longjin Pharmaceutical、Hainan Poly Pharm、Shanxi Zhendong Taisheng Pharmaceutical、Hainan Brilliant Pharmaceutical、Fujian Mindong Rejuenation Pharmaceuticalなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 注射用ニモジピン市場は、タイプとアプリケーションによって区分されます。世界の注射用ニモジピン市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別およびアプリケーション別の販売量、売上、予測に焦点を当てています。 【タイプ別セグメント】 2mg/本、4mg/本 【アプリケーション別セグメント】 病院薬局、小売店薬局、その他 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - 注射用ニモジピン製品概要 - タイプ別市場（2mg/本、4mg/本） - アプリケーション別市場（病院薬局、小売店薬局、その他） - 調査の目的 ・エグゼクティブサマリー - 世界の注射用ニモジピン販売量予測2017-2028 - 世界の注射用ニモジピン売上予測2017-2028 - 注射用ニモジピンの地域別販売量 - 注射用ニモジピンの地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別注射用ニモジピン販売量 - 主要メーカー別注射用ニモジピン売上 - 主要メーカー別注射用ニモジピン価格 - 競争状況の分析 - 企業M&A動向 ・タイプ別市場規模（2mg/本、4mg/本） - 注射用ニモジピンのタイプ別販売量 - 注射用ニモジピンのタイプ別売上 - 注射用ニモジピンのタイプ別価格 ・アプリケーション別市場規模（病院薬局、小売店薬局、その他） - 注射用ニモジピンのアプリケーション別販売量 - 注射用ニモジピンのアプリケーション別売上 - 注射用ニモジピンのアプリケーション別価格 ・北米市場 - 北米の注射用ニモジピン市場規模（タイプ別、アプリケーション別） - 主要国別の注射用ニモジピン市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパの注射用ニモジピン市場規模（タイプ別、アプリケーション別） - 主要国別の注射用ニモジピン市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋の注射用ニモジピン市場規模（タイプ別、アプリケーション別） - 主要国別の注射用ニモジピン市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米の注射用ニモジピン市場規模（タイプ別、アプリケーション別） - 主要国別の注射用ニモジピン市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカの注射用ニモジピン市場規模（タイプ別、アプリケーション別） - 主要国別の注射用ニモジピン市場規模（トルコ、サウジアラビア） ・企業情報 Shanxi PUDE Pharmaceutical、Reyoung Pharmaceutical、Double-Crane Pharmaceutical(Hainan)、Shanxi Hengda Pharmaceutical、Kunming Longjin Pharmaceutical、Hainan Poly Pharm、Shanxi Zhendong Taisheng Pharmaceutical、Hainan Brilliant Pharmaceutical、Fujian Mindong Rejuenation Pharmaceutical ・産業チェーン及び販売チャネル分析 - 注射用ニモジピンの産業チェーン分析 - 注射用ニモジピンの原材料 - 注射用ニモジピンの生産プロセス - 注射用ニモジピンの販売及びマーケティング - 注射用ニモジピンの主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - 注射用ニモジピンの産業動向 - 注射用ニモジピンのマーケットドライバー - 注射用ニモジピンの課題 - 注射用ニモジピンの阻害要因 ・主な調査結果 |
Market Analysis and Insights: Global Nimodipine for Injection Market
Due to the COVID-19 pandemic, the global Nimodipine for Injection market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, 2mg/Bottle accounting for % of the Nimodipine for Injection global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospital Pharmacy segment is altered to an % CAGR throughout this forecast period.
China Nimodipine for Injection market size is valued at US$ million in 2021, while the US and Europe Nimodipine for Injection are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Nimodipine for Injection landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
The global key manufacturers of Nimodipine for Injection include Shanxi PUDE Pharmaceutical, Reyoung Pharmaceutical, Double-Crane Pharmaceutical(Hainan), Shanxi Hengda Pharmaceutical, Kunming Longjin Pharmaceutical, Hainan Poly Pharm, Shanxi Zhendong Taisheng Pharmaceutical, Hainan Brilliant Pharmaceutical and Fujian Mindong Rejuenation Pharmaceutical. etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Nimodipine for Injection Scope and Segment
Nimodipine for Injection market is segmented by Specification and by Application. Players, stakeholders, and other participants in the global Nimodipine for Injection market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Specification and by Application for the period 2017-2028.
Segment by Specification
2mg/Bottle
4mg/Bottle
Segment by Application
Hospital Pharmacy
Retail Pharmacy
Others
By Company
Shanxi PUDE Pharmaceutical
Reyoung Pharmaceutical
Double-Crane Pharmaceutical(Hainan)
Shanxi Hengda Pharmaceutical
Kunming Longjin Pharmaceutical
Hainan Poly Pharm
Shanxi Zhendong Taisheng Pharmaceutical
Hainan Brilliant Pharmaceutical
Fujian Mindong Rejuenation Pharmaceutical
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
1 Study Coverage
1.1 Nimodipine for Injection Product Introduction
1.2 Market by Specification
1.2.1 Global Nimodipine for Injection Market Size Growth Rate by Specification, 2017 VS 2021 VS 2028
1.2.2 2mg/Bottle
1.2.3 4mg/Bottle
1.3 Market by Application
1.3.1 Global Nimodipine for Injection Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Nimodipine for Injection Sales Estimates and Forecasts 2017-2028
2.2 Global Nimodipine for Injection Revenue Estimates and Forecasts 2017-2028
2.3 Global Nimodipine for Injection Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Nimodipine for Injection Sales by Region
2.4.1 Global Nimodipine for Injection Sales by Region (2017-2022)
2.4.2 Global Sales Nimodipine for Injection by Region (2023-2028)
2.5 Global Nimodipine for Injection Revenue by Region
2.5.1 Global Nimodipine for Injection Revenue by Region (2017-2022)
2.5.2 Global Nimodipine for Injection Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Nimodipine for Injection Sales by Manufacturers
3.1.1 Global Top Nimodipine for Injection Manufacturers by Sales (2017-2022)
3.1.2 Global Nimodipine for Injection Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Nimodipine for Injection in 2021
3.2 Global Nimodipine for Injection Revenue by Manufacturers
3.2.1 Global Nimodipine for Injection Revenue by Manufacturers (2017-2022)
3.2.2 Global Nimodipine for Injection Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Nimodipine for Injection Revenue in 2021
3.3 Global Nimodipine for Injection Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Nimodipine for Injection Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Nimodipine for Injection Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Specification
4.1 Global Nimodipine for Injection Sales by Specification
4.1.1 Global Nimodipine for Injection Historical Sales by Specification (2017-2022)
4.1.2 Global Nimodipine for Injection Forecasted Sales by Specification (2023-2028)
4.1.3 Global Nimodipine for Injection Sales Market Share by Specification (2017-2028)
4.2 Global Nimodipine for Injection Revenue by Specification
4.2.1 Global Nimodipine for Injection Historical Revenue by Specification (2017-2022)
4.2.2 Global Nimodipine for Injection Forecasted Revenue by Specification (2023-2028)
4.2.3 Global Nimodipine for Injection Revenue Market Share by Specification (2017-2028)
4.3 Global Nimodipine for Injection Price by Specification
4.3.1 Global Nimodipine for Injection Price by Specification (2017-2022)
4.3.2 Global Nimodipine for Injection Price Forecast by Specification (2023-2028)
5 Market Size by Application
5.1 Global Nimodipine for Injection Sales by Application
5.1.1 Global Nimodipine for Injection Historical Sales by Application (2017-2022)
5.1.2 Global Nimodipine for Injection Forecasted Sales by Application (2023-2028)
5.1.3 Global Nimodipine for Injection Sales Market Share by Application (2017-2028)
5.2 Global Nimodipine for Injection Revenue by Application
5.2.1 Global Nimodipine for Injection Historical Revenue by Application (2017-2022)
5.2.2 Global Nimodipine for Injection Forecasted Revenue by Application (2023-2028)
5.2.3 Global Nimodipine for Injection Revenue Market Share by Application (2017-2028)
5.3 Global Nimodipine for Injection Price by Application
5.3.1 Global Nimodipine for Injection Price by Application (2017-2022)
5.3.2 Global Nimodipine for Injection Price Forecast by Application (2023-2028)
6 North America
6.1 North America Nimodipine for Injection Market Size by Specification
6.1.1 North America Nimodipine for Injection Sales by Specification (2017-2028)
6.1.2 North America Nimodipine for Injection Revenue by Specification (2017-2028)
6.2 North America Nimodipine for Injection Market Size by Application
6.2.1 North America Nimodipine for Injection Sales by Application (2017-2028)
6.2.2 North America Nimodipine for Injection Revenue by Application (2017-2028)
6.3 North America Nimodipine for Injection Market Size by Country
6.3.1 North America Nimodipine for Injection Sales by Country (2017-2028)
6.3.2 North America Nimodipine for Injection Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe Nimodipine for Injection Market Size by Specification
7.1.1 Europe Nimodipine for Injection Sales by Specification (2017-2028)
7.1.2 Europe Nimodipine for Injection Revenue by Specification (2017-2028)
7.2 Europe Nimodipine for Injection Market Size by Application
7.2.1 Europe Nimodipine for Injection Sales by Application (2017-2028)
7.2.2 Europe Nimodipine for Injection Revenue by Application (2017-2028)
7.3 Europe Nimodipine for Injection Market Size by Country
7.3.1 Europe Nimodipine for Injection Sales by Country (2017-2028)
7.3.2 Europe Nimodipine for Injection Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Nimodipine for Injection Market Size by Specification
8.1.1 Asia Pacific Nimodipine for Injection Sales by Specification (2017-2028)
8.1.2 Asia Pacific Nimodipine for Injection Revenue by Specification (2017-2028)
8.2 Asia Pacific Nimodipine for Injection Market Size by Application
8.2.1 Asia Pacific Nimodipine for Injection Sales by Application (2017-2028)
8.2.2 Asia Pacific Nimodipine for Injection Revenue by Application (2017-2028)
8.3 Asia Pacific Nimodipine for Injection Market Size by Region
8.3.1 Asia Pacific Nimodipine for Injection Sales by Region (2017-2028)
8.3.2 Asia Pacific Nimodipine for Injection Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Nimodipine for Injection Market Size by Specification
9.1.1 Latin America Nimodipine for Injection Sales by Specification (2017-2028)
9.1.2 Latin America Nimodipine for Injection Revenue by Specification (2017-2028)
9.2 Latin America Nimodipine for Injection Market Size by Application
9.2.1 Latin America Nimodipine for Injection Sales by Application (2017-2028)
9.2.2 Latin America Nimodipine for Injection Revenue by Application (2017-2028)
9.3 Latin America Nimodipine for Injection Market Size by Country
9.3.1 Latin America Nimodipine for Injection Sales by Country (2017-2028)
9.3.2 Latin America Nimodipine for Injection Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
9.3.6 Colombia
10 Middle East and Africa
10.1 Middle East and Africa Nimodipine for Injection Market Size by Specification
10.1.1 Middle East and Africa Nimodipine for Injection Sales by Specification (2017-2028)
10.1.2 Middle East and Africa Nimodipine for Injection Revenue by Specification (2017-2028)
10.2 Middle East and Africa Nimodipine for Injection Market Size by Application
10.2.1 Middle East and Africa Nimodipine for Injection Sales by Application (2017-2028)
10.2.2 Middle East and Africa Nimodipine for Injection Revenue by Application (2017-2028)
10.3 Middle East and Africa Nimodipine for Injection Market Size by Country
10.3.1 Middle East and Africa Nimodipine for Injection Sales by Country (2017-2028)
10.3.2 Middle East and Africa Nimodipine for Injection Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Shanxi PUDE Pharmaceutical
11.1.1 Shanxi PUDE Pharmaceutical Corporation Information
11.1.2 Shanxi PUDE Pharmaceutical Overview
11.1.3 Shanxi PUDE Pharmaceutical Nimodipine for Injection Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Shanxi PUDE Pharmaceutical Nimodipine for Injection Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Shanxi PUDE Pharmaceutical Recent Developments
11.2 Reyoung Pharmaceutical
11.2.1 Reyoung Pharmaceutical Corporation Information
11.2.2 Reyoung Pharmaceutical Overview
11.2.3 Reyoung Pharmaceutical Nimodipine for Injection Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Reyoung Pharmaceutical Nimodipine for Injection Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Reyoung Pharmaceutical Recent Developments
11.3 Double-Crane Pharmaceutical(Hainan)
11.3.1 Double-Crane Pharmaceutical(Hainan) Corporation Information
11.3.2 Double-Crane Pharmaceutical(Hainan) Overview
11.3.3 Double-Crane Pharmaceutical(Hainan) Nimodipine for Injection Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Double-Crane Pharmaceutical(Hainan) Nimodipine for Injection Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Double-Crane Pharmaceutical(Hainan) Recent Developments
11.4 Shanxi Hengda Pharmaceutical
11.4.1 Shanxi Hengda Pharmaceutical Corporation Information
11.4.2 Shanxi Hengda Pharmaceutical Overview
11.4.3 Shanxi Hengda Pharmaceutical Nimodipine for Injection Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Shanxi Hengda Pharmaceutical Nimodipine for Injection Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Shanxi Hengda Pharmaceutical Recent Developments
11.5 Kunming Longjin Pharmaceutical
11.5.1 Kunming Longjin Pharmaceutical Corporation Information
11.5.2 Kunming Longjin Pharmaceutical Overview
11.5.3 Kunming Longjin Pharmaceutical Nimodipine for Injection Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Kunming Longjin Pharmaceutical Nimodipine for Injection Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Kunming Longjin Pharmaceutical Recent Developments
11.6 Hainan Poly Pharm
11.6.1 Hainan Poly Pharm Corporation Information
11.6.2 Hainan Poly Pharm Overview
11.6.3 Hainan Poly Pharm Nimodipine for Injection Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Hainan Poly Pharm Nimodipine for Injection Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Hainan Poly Pharm Recent Developments
11.7 Shanxi Zhendong Taisheng Pharmaceutical
11.7.1 Shanxi Zhendong Taisheng Pharmaceutical Corporation Information
11.7.2 Shanxi Zhendong Taisheng Pharmaceutical Overview
11.7.3 Shanxi Zhendong Taisheng Pharmaceutical Nimodipine for Injection Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Shanxi Zhendong Taisheng Pharmaceutical Nimodipine for Injection Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Shanxi Zhendong Taisheng Pharmaceutical Recent Developments
11.8 Hainan Brilliant Pharmaceutical
11.8.1 Hainan Brilliant Pharmaceutical Corporation Information
11.8.2 Hainan Brilliant Pharmaceutical Overview
11.8.3 Hainan Brilliant Pharmaceutical Nimodipine for Injection Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Hainan Brilliant Pharmaceutical Nimodipine for Injection Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Hainan Brilliant Pharmaceutical Recent Developments
11.9 Fujian Mindong Rejuenation Pharmaceutical
11.9.1 Fujian Mindong Rejuenation Pharmaceutical Corporation Information
11.9.2 Fujian Mindong Rejuenation Pharmaceutical Overview
11.9.3 Fujian Mindong Rejuenation Pharmaceutical Nimodipine for Injection Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 Fujian Mindong Rejuenation Pharmaceutical Nimodipine for Injection Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Fujian Mindong Rejuenation Pharmaceutical Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Nimodipine for Injection Industry Chain Analysis
12.2 Nimodipine for Injection Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Nimodipine for Injection Production Mode & Process
12.4 Nimodipine for Injection Sales and Marketing
12.4.1 Nimodipine for Injection Sales Channels
12.4.2 Nimodipine for Injection Distributors
12.5 Nimodipine for Injection Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Nimodipine for Injection Industry Trends
13.2 Nimodipine for Injection Market Drivers
13.3 Nimodipine for Injection Market Challenges
13.4 Nimodipine for Injection Market Restraints
14 Key Findings in The Global Nimodipine for Injection Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer